PEPID Pulse
  • Blog
  • Alerts
  • Press
  • pepid.com
Select Page
First P13K inhibitor for Breast Cancer Gets FDA Approved

First P13K inhibitor for Breast Cancer Gets FDA Approved

by PEPID Newsroom | May 24, 2019 | Alerts

Pigray (alpelisib) tablets have been FDA approved to treat breast cancer in combination with FDA-approved endocrine therapy fulvestrant. Pigray is approved for postmenopausal women, and men, with hormone receptor (HR)-positive, human epidermal growth factor receptor 2...

Recent Posts

  • Dementia in the Emergency Department: Recognizing Delirium, Anticholinergic Burden, and the “Acting Different” Presentation
  • Heat-Related Illness in the Emergency Department: Recognition, Cooling, and the High-Risk Patient
  • EMS Week in Practice: Strengthening the Prehospital-to-ED Continuum for Better Patient Outcomes
  • Sleep Awareness Week: Why Sleep Health Should Be Part of Every Wellness Visit
  • Autism Acceptance Month: Autism in Clinical Practice—Communication Strategies and Considerations for Better Care

Categories

  • Alerts
  • Emergency Medicine
  • Featured Posts
  • Nursing
  • Pharmacy
  • Press & Media
  • Primary Care
  • Uncategorized
PEPID, LLC. All rights reserved